Diversity Management, News and Updates
Originally published on Abbott.com – Recurrent irregular heartbeat–also known as atrial fibrillation–impacts more than 16 million people globally – Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation Abbott announced first enrollments in the TactiFlex PAF IDE study to evaluate a new…
Originally published on sanofi.com. The havoc caused by the COVID-19 pandemic continues to disrupt daily life, but its reach goes deeper and further with mounting consequences for cancer patients who need ongoing treatment. Hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease,…
Kaiser Permanente Moanalua Medical Center is recognized as “high performing” in the treatment of chronic obstructive pulmonary disease, or COPD, and congestive heart failure by U.S. News & World Report. High performers are based on evaluation of the more than 4,500 medical centers and designate the top 10th percentile of hospitals nationwide.
In the health care field, telehealth has emerged as a way to provide advice and treatment to patients in a safe, convenient, and touchless fashion. During the COVID-19 pandemic, Kaiser Permanente quickly ramped up to increase its ability to offer its members access to remote guidance and care. Since March,…
Originally published on marriott.com. The 80-room W Gramado is expected to open in 2023. Marriott International, Inc. (NASDAQ: MAR) today announced that it has signed an agreement with KJP Participaçoes LTD to bring the W Hotels brand to Gramado, a mountain resort town in the Brazil’s southernmost state, Rio Grande…
Originally published on Dow.com Answering the industry needs of high performance, consumer convenience, and recyclability, Dow is excited to announce an innovative and revolutionary brand extension to the family of INNATE™ Precision Packaging Resins. INNATE™ TF Polyethylene Resins for Tenter Frame Biaxial Orientation are bringing commercial viability to a long-desired packaging goal:…
Originally published on Comcast.com Customers can now say “Vota por La Voz” into their Bilingual X1 Voice Remote to cast votes for their favorite artists. Since 2017, Xfinity X1 customers have been able to use their voice remotes to cast votes for their favorite artists on NBC’s “The Voice.” X1 has since…
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation orbehavior.1SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.
Originally published on ATT.com The first blog in the series discussed how companies need to invest in creating Transformational DNA. The second blog defined the five characteristics of Transformational DNA. At its core, any service organization must embody humility. This means leading with listening. It’s been critical to ensuring adoption across our organization. As…
Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).